MNOV — MediciNova Inc
NASDAQ · Healthcare · Biotechnology
$1.44
+$0.00 (+0.35%)
MediciNova Inc (MNOV) is a biotechnology company listed on NASDAQ. It is led by Yuichi Iwaki M.D., Ph.D., based in 4275 Executive Square, La Jolla, CA, United States, 92037, with about 6 employees. MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Latest reported MNOV revenue for 2025-09-30 was $123.3K. Net income was -$9.2M. Revenue was down 8.4% from 2025-06-30 to 2025-09-30. MNOV currently screens at market cap $66.0M.
Use this MNOV page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MNOV quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MNOV SEC filings page. Lician reads the product cache first so this HTML stays unique to MediciNova Inc even when a live quote feed is slow.
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
MNOV Key Statistics
Market Cap
$65.96M
Volume
83,651
Previous Close
$1.53
Day Range
$1.49 – $1.58
P/B Ratio
1.66
EPS
-$0.23
Revenue
$0.00
Net Income
-$11.05M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
6
MNOV Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.00M | $0.00 | $4.04M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$11.05M | -$8.57M | -$14.07M | -$10.13M |
| EPS (Diluted) | -$0.23 | -$0.17 | -$0.29 | -$0.21 |
Total Assets
$55.88M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$40.36M
Operating Cash Flow
-$10.64M
Free Cash Flow
$0.00
MediciNova Inc Company Information
- Co-Founder, President, CEO & Chairman
- Yuichi Iwaki M.D., Ph.D.
- Headquarters
- 4275 Executive Square, La Jolla, CA, United States, 92037
- Website
- medicinova.com
- Phone
- 858 373 1500
- IPO / Founded
- 2005-02-08
- Sector
- Healthcare
- Industry
- Biotechnology